Medicinal product name Mirapexin
Pharmaceutical form Prolonged-release tablet
Strength 2.1 mg 
Information from the MAH on shortages No information on expected shortages
Legal status Rx Prescription (Pr.)
KZSL1 Next lowest cost medicine
 Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
ATC code N04BC05 Anti-parkinson drugs

Important notice

Additional information regarding the use for persons aged 75+

If used as "ANTI-PARKINSON DRUGS"
SubstanceClassComment
PramipexolumCSuitable for older persons, with specific cautions. Sedative. Start therapy under specialist supervision. Reduce the dose in even moderate renal insufficiency. The most common adverse effects are orthostatic hypotension, gastrointestinal symptoms, drowsiness, hallucinations, confusion and sudden bouts of falling asleep. Take interactions into account, especially with antipsychotics.

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Not available (according to the information provided by wholesalers) currently no information on availability from any wholesaler N30
(2,1 mg)
PA/Al/PVC blister 161.66 
KZSL1*
EU/1/97/051/023  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
* Indication about medicine on the List of state reimbursed medicines is just informative. Source of the information is the National Health Service. For details please visit the NHS website.

Registration information

Marketing authorisation No. EU/1/97/051/023
Date of authorisation Oct 8, 2009
Marketing authorisation holder, country Boehringer Ingelheim International GmbH, Germany